• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    W

    WB Games Montréal

    企业
    2,961论文总数
    4.4万引用总数

    WB Games Montréal Inc. is a Canadian video game developer based in Montreal, Quebec. It is a subsidiary of Warner Bros. Interactive Entertainment and is best known for developing Batman: Arkham Origins.

    论文量&引用量时间轴

    机构学者

    论文(2962)

    年份
    起
    –
    止
    排序
    1Effectiveness of Leniolisib in Reducing Infections among Patients with Activated Phosphoinositide 3-Kinase Δ Syndrome (APDS)
    Niraj C. Patel, Jessica Kuivinen,Sean D. MacKnight,M. Elizabeth M. Younger,Guillaume Germain, Susannah Ripley,François Laliberté, Jesse Fishman,Amanda Harrington

    APDS is a rare inborn error of immunity characterized by clinical manifestations, including recurrent infections. This real-world, retrospective analysis evaluated patient-reported infection rates before and after leniolisib initiation. Patients (aged ≥ 12 years) newly initiating leniolisib therapy were eligible for inclusion. Data were retrieved from PANTHERx Rare Pharmacy. Patient-reported infection rates during the baseline period (one year before leniolisib initiation) were compared with infection rates after leniolisib initiation (observation period; from initiation to end of data or death) using generalized estimating equations Poisson regression models with robust standard errors. Patients who had an infection assessment collected via a standardized questionnaire during the baseline and observation periods were included in the analysis (N = 71); subgroups for baseline infection rates (lower and higher than the median) and age (12–17 and ≥ 18 years) were also evaluated. The mean (SD) rate of infections per patient-year (PPY) decreased significantly—by 68

    2026Immunologic Research(2026)
    引用
    AI阅读
    加入学术空间
    2Genetic Analyses Across Cardiovascular Traits: Leveraging Genetic Correlations to Empower Locus Discovery and Prediction in Common Cardiovascular Diseases
    Paloma Jordà, Yiwei Lai, Amélie Jeuken,Louis-Philippe Lemieux Perreault,Elisabeth Goulet,Najim Lahrouchi,Anna Nozza, Michael W. Tanck, Peter Guerra,Julia Cadrin-Tourigny,Simon de Denus,Connie R. Bezzina,

    Common genetic variation detected by genome-wide association studies (GWAS) partially explains variability in the spectrum of cardiac phenotypes. In this work, we explore genetic correlations among 58 cardiac-related traits/diseases, detecting novel ones. We subsequently employ multi-trait analysis of GWAS (MTAG), which meta-analyzes genetically correlated traits, to improve genomic loci discovery and prediction in atrial fibrillation (AF), coronary artery disease (CAD), and heart failure (HF). We identify 19 novel loci specific for AF, 131 for CAD, and 141 for HF. Polygenic scores (PGS) in 15,177 Canadian individuals show similar results when PGS are derived from conventional GWAS versus MTAG summary statistics, although MTAG-PGS improve prediction and discrimination of CAD in females [∆R2 1.735

    2025npj Genomic Medicine(2025)引用:15
    引用
    AI阅读
    加入学术空间
    3Digital Health Technologies in the Accelerating Medicines Partnership® Schizophrenia Program.
    Johanna T. W. Wigman, Ann Ee Ching, Yoonho Chung,Habiballah Rahimi Eichi, Erlend Lane, Carsten Langholm,Aditya Vaidyam, Andrew Jin Soo Byun, Anastasia Haidar, Jessica Hartmann, Angela Nunez, Dominic Dwyer,

    Although meta-analytic studies have shown that 25-33% of those at Clinical High Risk (CHR) for psychosis transition to a first episode of psychosis within three years, less is known about estimating the risk of transition at an individual level. Digital phenotyping offers a novel approach to explore the nature of CHR and may help to improve personalized risk prediction. Specifically, digital data enable detailed mapping of experiences, moods and behaviors during longer periods of time (e.g., weeks, months) and offer more insight into patterns over time at the individual level across their routine daily life. However, while novel digital health technologies open up many new avenues of research, they also come with specific challenges, including replicability of results and the adherence of participants. This paper outlines the design of the digital component of the Accelerating Medicines Partnership® Schizophrenia Program (AMP SCZ) project, a large international collaborative project that follows individuals at CHR for psychosis over a period of two years. The digital component comprises one-year smartphone-based digital phenotyping and actigraphy. Smartphone-based digital phenotyping includes 30-item short daily self-report surveys and voice diaries as well as passive data capture (geolocation, on/off screen state, and accelerometer). Actigraphy data are collected via an Axivity wristwatch. The aim of this paper is to describe the design and the three goals of the digital measures used in AMP SCZ to: (i) better understand the symptoms, real-life experiences, and behaviors of those at CHR for psychosis, (ii) improve the prediction of transition to psychosis and other health outcomes in this population based on digital phenotyping and, (iii) serve as an example for replicable and ethical research across geographically diverse regions and cultures. Accordingly, we describe the rationale, protocol and implementation of these digital components of the AMP SCZ project. **Link to video interview: https://vimeo.com/1060935583 *.

    2025Schizophrenia(2025)引用:7
    引用
    AI阅读
    加入学术空间
    4Body Fluid Biomarkers and Psychosis Risk in the Accelerating Medicines Partnership® Schizophrenia Program: Design Considerations.
    Diana O. Perkins, Clark D. Jeffries,Scott R. Clark,Rachel Upthegrove, Cassandra M. J. Wannan,Naomi R. Wray,Qingqin S. Li,Kim Q. Do,Elaine Walker,G. Paul Amminger,Alan Anticevic,David Cotter,

    Advances in proteomic assay methodologies and genomics have significantly improved our understanding of the blood proteome. Schizophrenia and psychosis risk are linked to polygenic scores for schizophrenia and other mental disorders, as well as to altered blood and saliva levels of biomarkers involved in hormonal signaling, redox balance, and chronic systemic inflammation. The Accelerating Medicines Partnership® Schizophrenia (AMP®SCZ) aims to ascertain biomarkers that both predict clinical outcomes and provide insights into the biological processes driving clinical outcomes in persons meeting CHR criteria. AMP®SCZ will follow almost 2000 CHR and 640 community study participants for two years, assessing biomarkers at baseline and two-month follow-up including the collection of blood and saliva samples. The following provides the rationale and methods for plans to utilize polygenic risk scores for schizophrenia and other disorders, salivary cortisol levels, and a discovery-based proteomic platform for plasma analyses. We also provide details about the standardized methods used to collect and store these biological samples, as well as the study participant metadata and quality control measures related to preanalytical factors that could influence the values of the biomarkers. Finally, we discuss our plans for analyzing the results of blood- and saliva-based biomarkers. Watch Dr. Perkins discuss their work and this article: https://vimeo.com/1062879582?share=copy#t=0 .

    2025Schizophrenia(2025)引用:6
    引用
    AI阅读
    加入学术空间
    5Decolonizing Global Health: a Scoping Review of Its Key Components, Proposed Actions, and Contributors.
    Michelle Amri, Jan Filart, Jinny Yang, Johanna Manga, Kathryn Barrett,Jesse B. Bump

    Although there has been attention paid to decolonizing global health, there is no consensus around the concept. To act in the face of various crises, including neocolonialism, there is a need to understand the key components of this concept within mainstream global health, how it can be acted on, and who is contributing to these discussions. A scoping review was undertaken to assess the academic literature for discussions on decolonizing global health. The PRISMA guidelines for Scoping Reviews (PRISMA-ScR) were used to guide reporting. OVID Medline, OVID Embase, EBSCO CINAHL Plus, Web of Science Core Collection, PAIS Index, Worldwide Political Science Abstracts, and the International Bibliography of the Social Sciences databases were searched from inception to August 8, 2023. The inclusion criterion was that texts had to: (i) use the exact phrasing of “decoloni* global health” or “anticolonial global health,” (ii) include substantive discussion of what decolonizi* global health or anticolonial global health means (i.e., single mentions that do not include an explanation, elaboration, or context were excluded), and (iii) be published in English. When analyzing how scholars understand “decolonizing global health”, its meaning is rooted in three key components: (i) power asymmetries between the global north and south; (ii) a legacy of colonialism in global health or neocolonialism; and (iii) epistemic injustice. The second part of the analysis looked to understand if decolonizing global health can be acted on, and if so, how? The analysis demonstrated that decolonization of global health involves: (i) overhauling existing power structures; (ii) establishing agency and self-determination of the global south; (iii) epistemic reformation and epistemic and ontological pluralism; (iv) education; and (v) inclusivity, solidarity, and allyship. Lastly, in assessing which scholars’ work was retrieved in this systematic search of the literature, most first authors were situated in the Americas Region (n = 45/99; 46

    2025Global Health Research and Policy(2025)引用:6
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 2962 篇论文

    合作机构(100)

    Hamburg Süd合作论文 72
    McGill University合作论文 68
    波士顿大学合作论文 38
    华盛顿州立大学温哥华校区合作论文 21
    哈利法克斯银行合作论文 20
    蒙特利尔大学合作论文 19
    圣弗朗西斯科州立大学合作论文 14
    汉密尔顿手表公司合作论文 13
    St. Louis Community College合作论文 12
    阿姆斯特丹自由大学合作论文 11

    机构统计